hero-press-releases-1

Newsroom

News

External stories on biodesix

Posts in: EGFR

Exploratory Analysis of Patients with NSCLC | Biodesix

Results from a analysis suggest VeriStrat may be selective of positive clinical response for ficlatuzumab plus gefitinib over gefitinib alone.

Protein Test Found to Boost NSCLC Survival, Costs (MedPage Today)

Choosing second-line therapy on the basis of a protein-expression test modestly improved survival in patients with advanced non-small cell lung cancer.

Genetic Engineering News | Biodesix

Trial Shows Biodesix Assay Predicts Breast Cancer Response to Femara (Genetic Engineering News)

Serum Profiling Making Mark on Predictive Medicine | Biodesix

Veristrat from Biodesix is an example of a serum-based test used in the clinic that can predict response to a second-line biotherapeutic treatment option.

Biodesix Targeting Pharma for VeriStrat (GenomeWeb)

Biodesix is looking to forge pharmaceutical partnerships to increase adoption of the test Veristrat.